Kourtney Sabala
Psychiatric/Mental Health · North Platte, NENPI 1043760960
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,165 of the $3,424 with a category attached, or 63.2%. 14 manufacturers reported payments, led by Johnson & Johnson at 44.1% of the total. Reporting peaked in 2024 at $2,100 and has fallen 84.2% since, to $332 in 2025.
Across 148 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$987
- Otsuka America Pharmaceutical, Inc.$434
- Alkermes, Inc.$103
- Axsome Therapeutics, Inc.$99
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$96
- plus $196 from 8 others
What the payments were for
- Travel & lodging$1,21135%
- Food & beverage$2,16563%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 11 | $1,509 |
| AbbVie | 86 | $987 |
| Otsuka America Pharmaceutical, Inc. | 24 | $434 |
| Alkermes, Inc. | 6 | $103 |
| Axsome Therapeutics, Inc. | 6 | $99 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $96 |
| Optinose US, Inc. | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Biogen | 1 | $25 |
| Corium, LLC | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$1,247
How this compares
$3,424 in reported general payments places this provider in the 75th percentile of 255 psychiatric/mental health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 18 | $29,775 |
| RexultiBrexpiprazole | 16 | $24,862 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,324 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 37 | $4,770 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,650 |
| DayvigoLemborexant | 12 | $3,779 |
| Methylphenidate ErMethylphenidate Hcl | 13 | $1,644 |
| Duloxetine Hcl | 29 | $1,481 |
| Olanzapine | 51 | $986 |
| Risperidone | 67 | $932 |
| Aripiprazole | 51 | $919 |
| Oxcarbazepine | 27 | $798 |
| Lamotrigine | 71 | $652 |
| Clonazepam | 76 | $600 |
| Trazodone Hcl | 66 | $596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $96 | $29,77518 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $434 | $24,86216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in North Platte
- Dacia OakesonHastings$32K
- Margaret Emersonla Vista$30K
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
- Sherry KropatschGrand Island$11K
- Virginia SmithOmaha$11K
- Christina HadleyOmaha$11K
- Suzanne GreggHastings$11K
- Helen TrotterLincoln$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.